<scp>LAPTM</scp>4B gene polymorphism augments the risk of cancer: Evidence from an updated meta‐analysis

Hashemi, Mohammad; Bahari, Gholamreza; Tabasi, Farhad; Markowski, Jarosław; Małecki, Andrzej; Ghavami, Saeid; Łos, Marek

doi:10.1111/jcmm.13896

Cited by 10 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been proposed that environmental and genetic factors contribute to cancer development [53,54]. Single nucleotide polymorphisms (SNPs) can be considered as biological markers that help scientists to recognize genes that are related to cancer [55].…”

Section: Discussionmentioning

confidence: 99%

Association between PD-1 and PD-L1 Polymorphisms and the Risk of Cancer: A Meta-Analysis of Case-Control Studies

Hashemi

Karami

Sarabandi

et al. 2019

Cancers

Self Cite

View full text Add to dashboard Cite

A number of case-control studies regarding the association of the polymorphisms in the programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) genes with the risk of cancer have yielded inconsistent findings. Therefore, we have conducted a comprehensive, updated meta-analysis study to identify the impact of PD-1 and PD-L1 polymorphisms on overall cancer susceptibility. The findings revealed that PD-1 rs2227981 and rs11568821 polymorphisms significantly decreased the overall cancer risk (Odds Ratio (OR) = 0.82, 95% CI = 0.68–0.99, p = 0.04, TT vs. CT+CC; OR = 0.79, 95% CI = 0.67–0.94, p = 0.006, AG vs. GG, and OR = 0.82, 95% CI = 0.70–0.96, p = 0.020, AG+AA vs. GG, respectively), while PD-1 rs7421861 polymorphism significantly increased the risk of developing cancer (OR = 1.16, 95% CI = 1.02–1.33, p = 0.03, CT vs. TT). The PD-L1 rs4143815 variant significantly decreased the risk of cancer in homozygous (OR = 0.62, 95% CI = 0.41–0.94, p = 0.02), dominant (OR = 0.70, 95% CI = 0.50–0.97, p = 0.03), recessive (OR = 0.76, 95% CI = 0.60–0.96, p = 0.02), and allele (OR = 0.78, 95% CI = 0.63–0.96, p = 0.02) genetic models. No significant association between rs2227982, rs36084323, rs10204525, and rs2890658 polymorphisms and overall cancer risk has been found. In conclusions, the results of this meta-analysis have revealed an association between PD-1 rs2227981, rs11568821, rs7421861, as well as PD-L1 rs4143815 polymorphisms and overall cancer susceptibility.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between PD-1 and PD-L1 Polymorphisms and the Risk of Cancer: A Meta-Analysis of Case-Control Studies

Hashemi

Karami

Sarabandi

et al. 2019

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…LAPTM4B is an essential membrane protein that contains multiple lysosomal targeting motifs at the C-terminus and colocalizes with endosomal and lysosomal markers in anaphase [ 10 , 11 ]. LAPTM4B is considered a pro-oncogene and can be abnormally upregulated in a variety of malignant solid tumors.…”

Section: Discussionmentioning

confidence: 99%

LAPTM4B promotes the progression of nasopharyngeal cancer

Su¹,

Luo²,

Zhang³

et al. 2020

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

Lysosomal protein transmembrane 4 beta (LAPTM4B) is a protein that contains four transmembrane domains. The impact of LAPTM4B on the malignancy of nasopharyngeal carcinoma (NPC) remains unclear. In the present study, we aimed to investigate the role of LAPTM4B in NPC. NPC tissue samples were used to evaluate the expression of LAPTM4B and its relationship with patient prognosis. Furthermore, we inhibited the expression of LAPTM4B in NPC cell lines and examined the effects of LAPTM4B on NPC cell proliferation, migration, and invasion. We found that LAPTM4B protein was mainly localized in the cytoplasm and intracellular membranes of NPC cells. LAPTM4B protein was upregulated in NPC tissues and cell lines. High LAPTM4B expression was closely related to pathological subtypes and disease stages in NPC patients. NPC patients with high LAPTM4B expression had a worse prognosis. LAPTM4B knockdown inhibited the proliferation, migration, and invasion ability of NPC cells. LAPTM4B plays a cancer-promoting role in the progression of NPC and may be a potential target for NPC therapy.

show abstract

“…LAPTM4B is a transmembrane protein involved in endosomal sorting and regulation of proteins such as EGFR, whose degradation it suppresses (55). LAPTM4B over-expression has been identified as a prognostic marker in various cancers, with potential effects via modulation of cell proliferation and/or autophagy (56)(57)(58). A potential interaction between LAPTM4B and phosphoinositide metabolism is shown by the finding that it can bind and is…”

Section: O R I Gmentioning

confidence: 99%

Investigating Genetic Determinants of Plasma Inositol Status in Adult Humans

Weston

Pangilinan

Eaton

et al. 2022

The Journal of Nutrition

View full text Add to dashboard Cite

Background Myo-inositol (MI) is incorporated into numerous biomolecules, including phosphoinositides and inositol phosphates. Disturbance of inositol availability or metabolism is associated with various disorders, including neurological conditions and cancers, while supplemental MI has therapeutic potential in conditions such as depression, polycystic ovary syndrome and congenital anomalies. Inositol status may be influenced by diet, synthesis, transport, utilisation and catabolism. Objectives We aimed to investigate potential genetic regulation of circulating MI status and to evaluate correlation of MI concentration with other metabolites. Methods Gas chromatography mass spectrometry was used to determine plasma MI concentration of more than 2,000 healthy, young adults (aged 18–28 years) from the Trinity Student Study. Genotyping data was used to test association of plasma MI with SNPs in candidate genes, encoding inositol transporters and synthesising enzymes, and test for genome-wide association. We evaluated potential correlation of plasma MI with D-chiro inositol, glucose and other metabolites by Spearman's rank correlation. Results Mean plasma MI showed a small but significant difference between males and females (28.5 and 26.9 µM, respectively). Candidate gene analysis revealed several nominally significant associations with plasma MI, most notably for SLC5A11, encoding a sodium-coupled inositol transporter, also known as SMIT2 (sodium-dependent myo-inositol transporter 2). However, these did not survive correction for multiple testing. Subsequent testing for genome-wide association with plasma MI did not identify associations of genome-wide significance (p < 5 × 10–8). However, 8 SNPs exceeded the threshold for suggestive significant association with plasma MI concentration (p < 1 × 10–5), 3 of which were located within or close to genes: MTDH, LAPTM4B and ZP2. We found significant positive correlation of plasma MI concentration with concentration of D-chiro-inositol and several other biochemicals including glucose, methionine, betaine, sarcosine and tryptophan. Conclusion Our findings suggest potential for modulation of plasma MI in young adults by variation in SLC5A11 which is worthy of further investigation.

show abstract

LAPTM4B gene polymorphism augments the risk of cancer: Evidence from an updated meta‐analysis

Cited by 10 publications

References 20 publications

Association between PD-1 and PD-L1 Polymorphisms and the Risk of Cancer: A Meta-Analysis of Case-Control Studies

Association between PD-1 and PD-L1 Polymorphisms and the Risk of Cancer: A Meta-Analysis of Case-Control Studies

LAPTM4B promotes the progression of nasopharyngeal cancer

Investigating Genetic Determinants of Plasma Inositol Status in Adult Humans

Contact Info

Product

Resources

About